Monday, August 06, 2018

Calls For Urgent Law Change To Stop Romanian Online Doctor Sites Selling ‘Powerful’ Drugs To UK Customers

The Care Quality Commission has warned that an urgent change in the law is needed to clamp down on foreign-based online doctor sites 
England's health care regulator wants action over powerful and addictive drugs Loophole means sites avoid regulation by contracting Romanians and Bulgarians One, UK Meds, is promoted by celebrity doctor Christian Jessen, who has presented Channel 4 programmes
An urgent change in the law is needed to clamp down on foreign-based online doctor sites that sell prescription-only drugs, the Care Quality Commission is warning.
Daily Mail UK report continues:
England's health care regulator wants action over powerful and often addictive drugs that are being sent to people without proper consultations.
In many cases they are ordered by addicts to circumvent their own GPs. A loophole in legislation means websites are avoiding regulation by contracting their doctors to work from EU countries including Romania and Bulgaria.
The commission spoke out before a BBC Panorama investigation that found two companies providing potentially dangerous drugs without carrying out stringent checks.
One, UK Meds, is promoted by celebrity doctor Christian Jessen, who has presented Channel 4 programmes.
Panorama found the company was avoiding regulation as it hires doctors through a sister company EU General Practitioners in Romania.
Two former opiate addicts were asked to order prescription-only medication. One received the opiate-based painkiller dihydrocodeine, the other another powerful painkiller, pregabalin.
A spokesman for Dr Jessen said he was used by the company to present short information videos and didn't endorse specific products.
Professor Steve Field at the CQC warned the law 'does not allow us to have any oversight over companies outside England and that is a real problem'.
He added: 'We need to try and get the legislation changed so that people can't just bypass our regulatory activities.' 

No comments: